Middle East and Africa Cancer Chemotherapy Market Outlook (2021–2031)

Combining Surgical, Radiation, and Targeted Treatment Modalities

A key driver of the Middle East and Africa cancer chemotherapy market is the widespread adoption of multimodal oncology treatment strategies that integrate chemotherapy with surgery, radiation therapy, targeted therapies, and immunotherapy. Chemotherapy is often administered in the neoadjuvant setting to reduce tumor burden before surgical intervention and as adjuvant therapy to eradicate residual disease and reduce recurrence risk. This multimodal approach is standard in breast, colorectal, and other solid tumor protocols.

Chemotherapy also functions as a radiosensitizer, enhancing tumor response when combined with radiation therapy, particularly in locally advanced lung, head and neck, and gynecologic cancers. Clinics and cancer centers across GCC and North African oncology networks increasingly incorporate chemoradiation in standard practice.

Moreover, chemotherapy remains integral to combination regimens with targeted agents and immuno‑oncology drugs, especially for advanced and metastatic disease, where dual or triple modality protocols improve survival outcomes. In the Middle East, public and private oncology centers actively adopt such combinations as part of national guideline frameworks, while in Africa, these approaches are gaining traction in major urban hospitals.

This integration of therapies not only improves clinical outcomes but also reinforces chemotherapy's central role within evolving treatment paradigms, driving consistent demand.

AI Applications in Chemotherapy Personalization and Dosing

Artificial Intelligence (AI) enables personalized regimen design and optimized dosing strategies. Traditional chemotherapy dosing is largely protocol‑based and may not fully account for patient‑specific factors such as genetic variability, tumor heterogeneity, metabolism, and treatment response patterns. AI tools can integrate clinical records, genomic and biomarker data, imaging results, and longitudinal treatment outcomes to support individualized treatment decisions.

In the Middle East particularly in Saudi Arabia, the UAE, and select urban centers across Egypt and North Africa investments in digital health infrastructure and electronic medical records are enabling initial implementations of AI‑driven clinical decision support tools. These systems assist oncologists in identifying optimal chemotherapy combinations, adjusting dosing schedules based on early response, forecasting potential toxicities, and selecting complementary targeted agents where appropriate.

AI also has the potential to support real‑world evidence generation and clinical trial optimization by enabling patient stratification, predictive outcome modeling, and biomarker discovery. While adoption varies across the Middle East and Africa due to differences in digital readiness and healthcare investment, the growing focus on precision oncology and data interoperability sets the stage for expanded use of AI in chemotherapy optimization.

The "Middle East and Africa Cancer Chemotherapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Middle East and Africa Cancer Chemotherapy market size and forecast at regional and country levels for key market segments covered under the scope
• Middle East and Africa Cancer Chemotherapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Middle East and Africa Cancer Chemotherapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Middle East and Africa Cancer Chemotherapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Middle East and Africa Cancer Chemotherapy market report is divided into Turkiye, the UAE, Saudi Arabia, Bahrain, Oman, Egypt, South Africa and Africa, Algeria, Nigeria, Kuwait, and Qatar. South Africa held the largest share in 2024.

The most advanced chemotherapy markets in the Middle East and Africa include South Africa, Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman. South Africa and Saudi Arabia lead due to strong public funding, national healthcare strategy enhancements, and substantial investments in oncology centers and precision diagnostics. Chemotherapy utilization is high across major indications, with multidisciplinary care models increasingly integrating targeted therapies and immunotherapies where appropriate. UAE oncology centers in Dubai and Abu Dhabi provide advanced chemotherapy services complemented by international clinical collaborations. Qatar and Kuwait continue to expand cancer care infrastructure and improve chemotherapy access through public insurance coverage and integrated cancer programs.

In Egypt, the government's focus on scaling up oncology services, including chemotherapy delivery, has led to stronger public hospital systems and private sector involvement. Nigeria and Algeria are strengthening cancer care networks, expanding chemotherapy availability, and improving early diagnosis efforts. These programs aim to reduce treatment disparities and enhance clinical outcomes. Other sub‑Saharan African nations exhibit diverse access; cancer care capacity is concentrated in urban centers, and chemotherapy access remains constrained in rural and low‑income regions. Public health initiatives, international partnerships, and advocacy programs are working to enhance equitable access to chemotherapy drugs and supportive care. Across Middle East and Africa, urban populations show higher chemotherapy uptake and access to advanced regimens, while resource‑limited areas face challenges in infrastructure, trained personnel, and consistent drug supply. Policymaker efforts focus on workforce training, oncology referral networks, and drug procurement reforms to expand equitable chemotherapy access across the region.

• The report includes qualitative and quantitative data in the Middle East and Africa Cancer Chemotherapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the Middle East and Africa Cancer Chemotherapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Middle East and Africa Cancer Chemotherapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Middle East and Africa Cancer Chemotherapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover Middle East and Africa Cancer Chemotherapy market segments by therapy type, indication, distribution channel, and geography across Turkiye, the UAE, Saudi Arabia, Bahrain, Oman, Egypt, South Africa and Africa, Algeria, Nigeria, Kuwait, and Qatar. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Middle East and Africa Cancer Chemotherapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The Middle East and Africa Cancer Chemotherapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Middle East and Africa cancer chemotherapy market are:

• In July 2025, NeOnc Technologies signed a non‑binding US$ 50 million strategic term sheet with Quazar Investment to launch a dedicated clinical trials platform and expansion into the UAE, positioning the company to initiate and manage late‑stage oncology trials locally and strengthen clinical development infrastructure in MEA markets.
• In February 2025, Burjeel Holdings a leading healthcare provider in the GCC announced plans to establish a regional radiation oncology network after acquiring an 80% stake in Advanced Care Oncology Center in Dubai, expanding capacity for integrated oncology services, including chemotherapy, radiation therapy, and advanced diagnostics across the GCC.